Catégorie : Essais Cliniques

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder : From Bench Research to Confirmation in Human Trials, Rafael M. Bitencourt and Reinaldo N. Takahashi, 2018

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder : From Bench Research to Confirmation in Human Trials Rafael M. Bitencourt and Reinaldo N. Takahashi Frontiers in Neuroscience, 2018, 12, 502, 1-10. Doi : 10.3389/fnins.2018.00502   Post-traumatic stress disorder (PTSD) is characterized by poor adaptation to a traumatic experience. This disorder affects approximately 10% of people at some point in life. Current pharmacological therapies for PTSD have been shown to be inefficient and produce considerable side effects. Since the discovery of the involvement of the endocannabinoid (eCB) system in emotional memory processing, pharmacological manipulation of eCB signaling has become a therapeutic possibility for the treatment of [...]

Lire la suite

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder, Matthew N. Hill et al., 2018

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder Matthew N. Hill, Patrizia Campolongo, Rachel Yehuda and Sachin Pate Neuropsychopharmacology REVIEWS, 2018, 43, 80–102. doi : 10.1038/npp.2017.162   Exposure to stress is an undeniable, but in most cases surmountable, part of life. However, in certain individuals, exposure to severe or cumulative stressors can lead to an array of pathological conditions including posttraumatic stress disorder (PTSD), characterized by debilitating trauma-related intrusive thoughts, avoidance behaviors, hyperarousal, as well as depressed mood and anxiety. In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, [...]

Lire la suite

Cannabidiol as a Treatment for Mood Disorders : A Systematic Review – Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique, Jairo Vinicius Pinto et al., 2020,

Cannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195   Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]

Lire la suite

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomizedplacebo-controlled trial, Violaine Mongeau-Pérusse, et al., 2021

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomized placebo-controlled trial Violaine Mongeau-Pérusse, Suzanne Brissette, Julie Bruneau, Patricia Conrod, Simon Dubreucq, Guillaume Gazil, EmmanuelStip & DidierJutras-Aswad Addiction, 2021, 116, (9), 1-12. Doi : 10.1111/add.15417   ABSTRACT Background and Aims : Cocaine use disorder (CUD) is a significant public health concern for which no efficacious phar-macologicalinterventionsare available. Cannabidiol (CBD) has attracted considerable interest as a promisingtreatmentforaddiction. This study tested CBD efficacy for reducing craving and preventing relapse in people with CUD.DesignSingle-site double-blind randomized controlled superiority trial comparing CBD with placebo. Setting and Participants : Centre Hospitalier de l’Université de Montréal, Canada. Seventy-eight [...]

Lire la suite

Learning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance, Max Wolf et al., 2020

Learning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance Max Wolff, Ricarda Evens, Lea J. Mertens, Michael Koslowski, Felix Betzler, Gerhard Gründer and Henrik Jungaberle Frontiers in Psychiatry, February 2020 | Volume 11 | Article 5, 1-13. doi : 10.3389/fpsyt.2020.00005   The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate. This article presents a conceptual model that specifies potential psychological mechanisms underlying such change, and that shows substantial parallels between psychedelic therapy and cognitive behavioral therapy: We propose that in the carefully controlled [...]

Lire la suite

Real life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy, Lihi Bar-Lev Schleider et al., 2019

Real life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy Lihi Bar-Lev Schleider, Raphael Mechoulam, Naama Saban, Gal Meiri & Victor Novack Scientific Reports, Nature.com, 2019, 9, 200, 1-7 Doi : 10.1038/s41598-018-37570-y   There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of [...]

Lire la suite

Current state of evidence of cannabis utilization for treatment of autism spectrum disorders, Rumi Agarwal et al., 2019

Current state of evidence of cannabis utilization for treatment of autism spectrum disorders Rumi Agarwal, Shanna L. Burke and Marlaina Maddux BMC Psychiatry, 2019, 19, 328 Doi : 10.1186/s12888-019-2259-4   Abstract The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of [...]

Lire la suite

The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD), Charlotte M Pretzsch et al., 2019

The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) Charlotte M. Pretzsch, Bogdan Voinescu, Maria A. Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly and Gráinne M. McAlonan Journal of Psychopharmacology, 2019, Vol. 33, (9), 1141–1148 Doi : 10.1177/0269881119858306   Abstract Background : The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains [...]

Lire la suite

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use, Paulo Fleury-Teixeira et al., 2019

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, 2019, volume 10, Article 1146, 1-9. doi : 10.3389/fneur.2019.01145   Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]

Lire la suite

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities, Dana Barchel et al., 2019

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities Dana Barchel, Orit Stolar2, Tal De-Haan, Tomer Ziv-Baran, Naama Saban, Danny Or Fuchs, Gideon Koren and Matitiahu Berkovitch Frontiers in Pharmacology, 2019, volume 9, article 1521, 1-5 Doi : 10.3389/fphar.2018.01521   Objective : Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, [...]

Lire la suite